HC Wainwright Rates Incyte (INCY) buy, $140 Price Target
HC Wainwright maintains its positive outlook on Incyte with a $140 price target, a 23.50% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
HC Wainwright rated Incyte Corporation ($INCY) "buy" with a $140 price target on June 29, 2026.
Since the rating, $INCY is up 0.8% after 1 week, up 10.8% after 1 month and down 1.4% to date (from the $114.66 close on Jun 29, 2026).
INCY
Incyte Corporation
Key Points
- HC Wainwright reiterated its buy rating on Incyte Corporation (INCY) with a $140 price target on June 29, 2026.
- HC Wainwright's $140 price target implies 23.50% upside from Incyte Corporation's ($INCY) current $113.36 share price.
- Shares of NasdaqGS:INCY traded near $113.75 on Monday, with a market cap of $22.7 billion and a P/E ratio of 16.07.
- Insider buying activity was noted in June, and analysts have a consensus buy rating with a target mean price of $110.70.
Get $INCY trade alerts by text
We text you when insiders, Congress or big funds trade $INCY. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Incyte Corporation alert may contain errors. Disclosures
On June 29, 2026, HC Wainwright reiterated its buy rating on Incyte Corporation (NasdaqGS: INCY), setting a price target of $140. This move reflects continued confidence in Incyte's prospects by the analyst Mitchell S. Kapoor.
HC Wainwright & Co. vs. the S&P 500
Hypothetical returns from HC Wainwright & Co.'s disclosed trades, not real profit or advice. How we model this.
Incyte Corporation Stock Down 9.5%
Shares of Incyte Corporation traded near $113.75 on Monday. The company, with a market cap of approximately $22.7 billion, holds a P/E ratio of 16.07. Incyte has a 52-week low of $66.83 and a high of $115.56, with a 50-day moving average of $99.26 and a 200-day moving average of $97.33. The company's beta is 0.79, indicating relatively low volatility compared to the market.
$INCY price target
Incyte Corporation daily closes and this analyst's $140 target. Not advice.
Recent Earnings
Incyte reported revenue of about $5.36 billion, with a growth rate of 20.9%. The company achieved an EPS of $7.08, with a net margin of 26.7% and a return on equity of 30.8%. The next earnings report is anticipated on July 28, 2026.
Insider Buying and Selling at Incyte Corporation
Several insiders, including Otis Brawley, Edmund Harrigan, and Katherine High, purchased shares on June 8, 2026. These transactions involved a total of 11,079 shares, suggesting confidence in the company's future.
Analysts Set New Price Targets
On June 29, 2026, HC Wainwright & Co. reiterated its buy rating on Incyte with a $140 price target. UBS maintained its hold rating with a $113 target on June 26, while Truist Securities maintained a hold with a $105 target on June 22. Analysts have set a consensus buy recommendation with a target mean price of $110.70, based on 23 opinions.
About Incyte Corporation
Incyte Corporation is a biopharmaceutical company headquartered in Wilmington, Delaware. It focuses on discovering and developing therapeutics, particularly in oncology and hematology. The company markets several treatments, including Jakafi for myelofibrosis and Iclusig for leukemia. Led by CEO William J. Meury, Incyte employs around 2,844 people and collaborates with firms like Novartis and Lilly.
Bottom Line
HC Wainwright's reiterated buy rating on Incyte Corporation with a $140 target underscores analyst confidence in the company's growth potential. Incyte's recent earnings and insider buying activity highlight its strong position in the biopharmaceutical sector. As always, remember that analyst ratings are based on past data and may not reflect current market conditions.
Related Filing Alerts
Source: HC Wainwright's rating change on $INCY (Jun 29, 2026). Written by software, not financial advice. How we make alerts